The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01L | Ocular vascular disorder agents | |
| 4 | S01LA | Antineovascularisation agents | |
| 5 | S01LA05 | Aflibercept |
| Active Ingredient | Description | |
|---|---|---|
| Aflibercept |
Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| EYLEA 114.3 mg/ml Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EYLEA 40 mg/ml Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EYLEA 40 mg/mL Solution for injection in pre-filled syringe | European Medicines Agency (EU) | MPI, EU: SmPC | |
| YESAFILI Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
